Based on a recent large-scale single-cell sequencing study of MSI-H CRC patients undergoing neoadjuvant PD-1 blockade (NCT03926338/GSE205506), we characterized the cell features and global dynamics of ENTPD3+ CAFs in CRC immunotherapy (Figure 8A). Here, ENTPD3 is linked to colorectal carcinoma.